Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

SA Transcripts 162.33K Followers Follow Camp4 Therapeutics Corporation ( CAMP ) Analyst/Investor Day September 28, 2026 12:00 PM EDT Company Participants Joshua Mandel-Brehm - CEO, President & Director Daniel Tardiff - Chief Scientific Officer Yuri Maricich - Chief Medical Officer Mike Graglia Conference Call Participants Stephane Auvin Anupam Rama - JPMorgan Chase & Co, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Seema Sheoran - Rodman & Renshaw Research Yun Zhong - Wedbush Securities Inc., Research Division Presentation Unknown Attendee Good afternoon, and welcome to the Camp4 Therapeutics Analyst Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Camp4 website following the conclusion of the event. I'd now like to turn the call over to Josh Mandel-Brehm, Chief Executive Officer at Camp4 Therapeutics. Please go ahead, Josh. Joshua Mandel-Brehm CEO, President & Director Good afternoon, everybody, and thank you for joining us for our first-ever analyst event to discuss CMP-002 for the treatment of SYNGAP1. We are going to be making some forward-looking statements today as part of the discussion, and I encourage everybody to visit our public filings for more information. We have a wonderful agenda for you all today. I'm going to take some time to make some briefly prepared remarks but then you'll have the opportunity to hear from Beata, a parent and caregiver to their daughter Kasia, about their family's experience living with SYNGAP1. This will be followed by our CSO, Dan Tardiff; and our CMO, Yuri Maricich, who're going to review our preclinical data and provide an overview of our ASCEND Phase I/II clinical study. Next, you're going to hear from the CEO of CURE SYNGAP1, Mike Graglia, who will share his thoughts on the importance of our Phase I/II study and how we collaborated